



Characterization of *Clostridium difficile* strains isolated in Italy from 2007 to 2011 and comparative analysis of the predominant PCR-ribotypes

P. Spigaglia, F. Barbanti, F. Wasels, I. Moura, P. Mastrantonio

Department of Infectious, Parasitic and Immuno-mediated Diseases, Istituto Superiore di Sanità, Rome, Italy (patrizia.spigaglia@iss.it)

Introduction and Purpose

The European surveillance performed in 2008 indicated *Clostridium difficile* PCR-ribotypes 078/126 and 018 as two emerging virulent types. The first type includes hypervirulent strains that cause infections in both hospital settings and community and that are currently spread in different European countries; the second type is predominantly isolated in Italy where it is the major cause of severe infections and outbreaks occurred in the last years. While type 078/126 has variations in the locus of pathogenicity (PaLoc), in particular in the toxin genes, and it is considered a toxin variant type, strains 018 are non-toxin variant, as

the majority of isolates causing infections in Europe. In this study, 131 Italian clinical isolates isolated from 2007 and 2011 were characterized and a selection of strains 018 and 078/126 were investigated for sporulation and adhesion to Caco-2 cells. Strains were also compared by in vitro competition assays.

Table 1. Characteristics of the 131 *C. difficile* clinical isolates analyzed in the study

| PCR-ribotype | Year of isolation (n. of strains) | ERY | | CLI | | MXF | | RIF | |
|--------------|-----------------------------------|------------------------|-----------------|-----------|-----------------|-----------|-----------------|-------------|-----------------|
| | | MIC range ^a | % of resistance | MIC range | % of resistance | MIC range | % of resistance | MIC range | % of resistance |
| 018 | 2007 (8) | | | | | | | | |
| | 2008 (20) | 1- >256 | 99% | 3- 16 | 93% | 1- >32 | 99% | 50.002- >32 | 85% |
| | 2009 (23) | | | | | | | | |
| | 2010 (27) | | | | | | | | |
| 078/126 | 2008 (7) | 0.75- >256 | 89% | 3- >256 | 50% | 0.38- 12 | 33% | 50.002- >32 | |
| | 2009 (16) | | | | | | | | |
| | 2010 (14) | | | | | | | | |
| | 2011 (1) | | | | | | | | |
| 095 | 2008 (5) | 0.75- >256 | 83% | 6- >256 | 83% | 0.5- >32 | 83% | 50.002- >32 | 83% |
| | 2009 (1) | | | | | 0.75 | | 50.002 | |
| 010 | 2010 (2) | | | | | | | | |
| | 2011 (1) | | | | | | | | |
| 014 | 2008 (1) | 0.75- >256 | 50% | | | 0.75- 8 | 50% | 50.002- >32 | 50% |
| | 2009 (1) | | | | | | | | |
| 106 | 2009 (2) | >256 | 100% | 6 | | >32 | 100% | 50.002 | |
| | 2010 (1) | >256 | 100% | 4 | 100% | 12 | 100% | >32 | 100% |
| 001 | 2009 (1) | | | 2 | | 2 | | 2 | |
| | 2010 (1) | | | 8 | | 1 | | 1 | |
| 002 | 2008 (1) | | | 2 | | 0.5 | | 50.002 | |
| | 2009 (1) | | | 2 | | 0.5 | | 50.002 | |
| 003 | 2008 (1) | >256 | 100% | >256 | 100% | 0.5 | | 50.002 | |
| | 2009 (1) | | | 4 | | 0.5 | | 50.002 | |
| 012 | 2008 (1) | | | 2 | | 0.5 | | 50.002 | |
| | 2009 (1) | | | 2 | | 0.5 | | 50.002 | |
| 015 | 2008 (1) | 1.6 | | 1.5 | | 0.75 | | 50.002 | |
| | 2009 (1) | | | 6 | | 1 | | 50.002 | |
| 116 | 2011 (1) | 0.75 | | 4 | | 0.5 | | 50.002 | |
| | 2010 (1) | | | 1 | | 0.5 | | 50.002 | |
| 131 | 2008 (1) | 0.75 | | 1.5 | | 0.75 | | 50.002 | |
| | 2009 (1) | | | 1.5 | | 0.75 | | 50.002 | |
| 137 | 2008 (1) | 0.75 | | 4 | | 0.5 | | 50.002 | |
| | 2009 (1) | | | 1.5 | | 0.75 | | 50.002 | |
| 212 | 2008 (1) | 0.75 | | 1.5 | | 0.75 | | 50.002 | |
| | 2009 (1) | | | 1.5 | | 0.75 | | 50.002 | |
| Total | 131 | 0.75- >256 | 90% | 1.5- >256 | 50% | 0.38- >32 | 80% | 50.002- >32 | 65% |

^a MIC values are reported in mg/L




Fig 1. Ratio between strains 018 and 078/126 from 2008 to 2011

Table 2. Multi-resistant strains identified in the study

| PCR-ribotype | N. of strains analyzed | N. of multi-resistant strains (%) | N. of strains resistant to | | | | | |
|--------------|------------------------|-----------------------------------|----------------------------|-----|-----|-----|-----|-----|
| | | | ERY | MXF | RIF | ERY | MXF | CLI |
| 018 | 91 | 85 (93) | 57 | 8 | 2 | 40 | | |
| 078/126 | 18 | 4 (22) | | | | | | |
| 095 | 6 | 5 (83) | | | | | | |
| 014 | 2 | 1 (50) | 1 | | | | | |
| 001 | 1 | 1 (100) | | | | | | 1 |

Methods

Bacterial strains. 131 *C. difficile* clinical isolates selected from the Istituto Superiore di Sanità (ISS) *C. difficile* national collection were included in this study. These strains were isolated from sporadic cases and outbreaks between 2007 and 2011 and were sent to ISS by different Italian hospitals for typing and/or molecular analysis. *C. difficile* C253, isolated in Italy (1987) and belonging to PCR-ribotype 012, were used as control strain.

Susceptibility test. Susceptibility to erythromycin (ERY), clindamycin (CLI), rifampicin (RIF), moxifloxacin (MXF), vancomycin (VAN) and metronidazole (MTZ) was determined by the E-test (AB Biodisk). The breakpoints used were 8 mg/L for ERY, CLI and MXF, and 32 mg/L for MTZ, in accordance with the CLSI interpretative categories approved for anaerobic bacteria (CLSI - Seventh Edition: Approved standard M11-A7. CLSI, Wayne, PA, USA, 2007). The breakpoints for RIF and VAN were 4 and 16 mg/L, respectively, in accordance with the CLSI interpretative categories approved for *Staphylococcus aureus* (CLSI - Eighteenth Informational Supplement M100-S18. CLSI, Wayne, PA, USA, 2008.), since no interpretative values were provided for anaerobes.

SlpA characterization. The gene encoding for the S-layer proteins precursor (SlpA) were amplified as already described (JCM, 2002, 40: 3470). PCR products were purified using the NucleoSpin Extract kit (Macherey-Nagel) and sequenced by the Big Dye Terminator v.1.1 Cycle Sequencing kit (Applied Biosystems) and an Applied Biosystems 3730 DNA Analyser. Sequences were analyzed and compared by the SeqMan and MegAlign in DNASTAR Lasergene[®] v8.0 software (DNASTAR Inc., Madison, WI). Comparisons of SlpA amino acid sequences were accomplished using the European Bioinformatics Institute ClustalW server.

Spore production and in vitro adhesion assay. Spore production was evaluated as already described (PLoS ONE 6(9): e24894. doi:10.1371/journal.pone.0024894). Briefly, *C. difficile* isolates were cultured in BHIS broth in anaerobic conditions at 35°C for 5 days. 500 µl of cultures were removed at 0, 24, 48 and 120h from the anaerobic chamber and heated at 60°C for 25 min to kill vegetative forms. Samples were then plated onto BHIS plates supplemented with 0.1% bile salt taurocholate to induce germination and enhance recovery of spores. Statistical analysis was performed using Mann and Whitney test with GraphPad Prism software. A p value < 0.05 was considered significant.

In vitro adhesion was performed on Caco-2 cells at 15 days (post confluent monolayers), after a treatment with 0.1 mM EGTA to disrupt intercellular junctions. Results were expressed as number of adherent bacteria per cell. Statistical analyses were performed using Mann and Whitney test with GraphPad Prism software. A p value < 0.05 was considered significant.

Growth competition assays. Growth competition assays were performed as already described (PNAS, 2010, 107:16964). Briefly, selected strains 018 and 078/126 were grown separately, mixed in a 1:1 ratio, and used to inoculate 25 ml of BHI broth. One hundred microliters were transferred to fresh 25-mL broth every 24 hours over three cycles. Aliquots were plated at the end of every cycle with and without the antibiotic of selection used. The selection coefficient s was calculated as $s = \ln(C1)/[t \times \ln(2)]$, where C1 is the competition index (calculated as the cfu ratio of the two strains used for each experiment at time t1, t2 and t3 divided by the same ratio at time t0) and t is the number of generations. Fitness of strains 078/126 was set to 1 and the relative fitness of type 018 was determined as $1 + s$. Statistical analysis was performed using GraphPad software.

Results

Among the 131 strains analyzed, the predominant PCR-ribotypes were 018 (69%) and 078/126 (14%), followed by 14 other types (Table 1). In 2007 only 9 strains were analyzed and 8 belong to PCR-ribotype 018. 73% of the strains (96/131) were multi-resistant and the majority of them (88%) were 018 (Table 2). The ratio between 018 and 078/126 increased from 2008 to 2011 (Fig. 1). In general, the majority of multi-resistant strains (84/96) were resistant to ERY, MXF and RIF. All strains were susceptible to VAN and MTZ. Interestingly, two new SlpA variants were found in strains 018 (Table 3). These variants have 99% identity with that of a strain 018 recently analyzed by Dingle et al. (J Infect Dis, 2013, 207: 675) and 89% identity with the SlpA of strains 078/126.

Table 3. Characteristics of 20 selected *C. difficile* strains belonging to PCR-ribotype 018 and 078/126

| Strains | Year | PCR-ribotype | Resistance to | ermB | Substitution in GyrA | Substitution in RpoB | SlpA sequence |
|-----------------------|------|--------------|-----------------|------|----------------------|---------------------------|---|
| C253 (control strain) | 1987 | 012 | ERY CLI RIF | + | Thr82 -Ile | Arg505 -Lys | Identical to AAZ05975 (strain HPA R13550) |
| 9411 | 2006 | 018 | ERY CLI MXF | + | Thr82 -Ile | | new type 1 |
| IT0601 | 2006 | 018 | ERY MXF | - | Thr82 -Ile | | new type 1 |
| IT0707 | 2007 | 018 | ERY CLI MXF | - | Thr82 -Ile | | new type 2 |
| IT0805 | 2008 | 018 | ERY CLI MXF RIF | - | Thr82 -Ile | Ser498 -Thr / Arg505 -Lys | n. d. |
| IT0839 | 2008 | 010 | ERY MXF RIF | - | Thr82 -Ile | Ser498 -Thr / Arg505 -Lys | new type 1 |
| IT0902 | 2009 | 018 | ERY MXF RIF | - | Thr82 -Ile | Arg505 -Lys | new type 1 |
| IT0926 | 2009 | 010 | ERY MXF RIF | - | Thr82 -Ile | Arg505 -Lys | new type 1 |
| IT1006 | 2010 | 018 | ERY CLI MXF RIF | - | Thr82 -Ile | Ser498 -Thr / Arg505 -Lys | new type 1 |
| IT1024 | 2010 | 018 | ERY MXF RIF | - | Thr82 -Ile | Arg505 -Lys | new type 1 |
| IT1118 | 2011 | 018 | ERY CLI MXF RIF | - | Thr82 -Ile | Arg505 -Lys | new type 1 |
| CDS | 1998 | 078/126 | ERY | - | | | Identical to AAZ05994 (strain HPA R13540) |
| 2355 | 2006 | 078/126 | ERY MXF | - | Thr82 -Ile | | Identical to AAZ05994 (strain HPA R13540) |
| IT0920 | 2008 | 078/126 | ERY CLI RIF | + | | | Identical to AAZ05994 (strain HPA R13540) |
| IT0844 | 2008 | 078/126 | ERY CLI MXF | + | Thr82 -Ile | | Identical to AAZ05994 (strain HPA R13540) |
| IT0844 | 2008 | 078/126 | ERY CLI MXF | - | Thr82 -Ile | | Identical to AAZ05994 (strain HPA R13540) |
| IT0918 | 2009 | 078/126 | ERY MXF | - | Thr82 -Ile | | Identical to AAZ05994 (strain HPA R13540) |
| IT0925 | 2009 | 078/126 | ERY | - | | | Identical to AAZ05994 (strain HPA R13540) |
| IT1004 | 2010 | 078/126 | ERY MXF | - | Thr82 -Ile | | Identical to AAZ05994 (strain HPA R13540) |
| IT1008 | 2010 | 078/126 | ERY MXF | - | Thr82 -Ile | | Identical to AAZ05994 (strain HPA R13540) |
| IT1106 | 2011 | 078/126 | ERY | - | | | Identical to AAZ05994 (strain HPA R13540) |

Among the 20 selected strains belonging to PCR-ribotype 018 and 078/126, an *ermB* gene was detected only in those highly resistant to both ERY and CLI (MIC ≥ 256 mg/L) (Table 3). Resistance to MXF and RIF was associated to amino acid substitutions in GyrA (Thr82 → Ile) and in RpoB (Ser498 → Thr and/or Arg505 → Lys), respectively. Sporulation was strain-dependent but, in general, more abundant for strains 018 after 48h (Fig. 2). A significantly higher adhesion to Caco-2 cells was observed for strains 018 (Fig. 3). Furthermore, growth competition assays indicated that strains 018 rapidly overcome strains 078/126 with a decrease in fitness for the latter (Table 4).

Fig. 2. Results of the in vitro sporulation assays performed on the selected strains 018 and 078/126. A: results obtained for each strain B: results expressed as average values




Fig. 3. Results of the in vitro adhesion assays performed on the selected strains 018 and 078/126




Table 4. Results of the in vitro growth competition assays performed on the selected strains 018 and 078/126

| Strains | 018 vs 078/126 | Ratio A/B ^a | | | Relative Fitness per generation ^b | P ^c | |
|---------|----------------|------------------------|------|------|--|----------------|---------|
| | | t1 | t2 | t3 | | | |
| 9411 | 2553 | 1.18 | 1.44 | 2.31 | 0.026 | 1.026 ± 0.000 | <0.0001 |
| 9411 | IT0844 | 1.11 | 1.36 | 2.00 | 0.021 | 1.021 ± 0.007 | <0.0001 |
| IT1118 | IT1106 | 1.19 | 1.28 | 2.40 | 0.021 | 1.024 ± 0.000 | <0.0001 |
| IT0916 | IT0820 | 1.17 | 1.25 | 2.00 | 0.021 | 1.021 ± 0.005 | <0.0001 |

^a Values represent the log₁₀(CFU) ratios at the end of each transfer (i.e. 8 generations).
^b Selection coefficient.
^c P-values related to 18 runs (P < 0.05).

^d Statistic of significance of difference in fitness related to strains P 018.

Conclusions

- Among 131 Italian *C. difficile* strains isolated between 2007 and 2011, 16 different PCR-ribotypes were identified. Types 018 (69%) and 078/126 (14%) were the predominant. Interestingly, the ratio between 018 and 078/126 increased from 2008 to 2011.
- 73% of the strains analyzed were multi-resistant and the majority of them were resistant to ERY, RIF and MXF. 88% of the multi-resistant strains belonged to PCR-ribotype 018.
- Comparative in vitro assays showed a significant higher production of spores and adhesion to Caco-2 cells for strains 018. Interestingly, two new SlpA variants were found in strains 018. These variants could contribute to the higher adhesion of these strains to the cells.
- Growth competition assays between strains 018 and 078/126 also demonstrated that the first becomes predominant in a short time. This peculiar behavior could allow a more rapid colonization of the intestine by strains 018 if maintained in vivo.
- All these characteristics may have played a role in the enhancement of virulence and in facilitating the spread of type 018 towards type 078/126 in Italian hospitals, even if further studies will be necessary to in depth investigate this emerging type.